Hopkins Lupus Cohort

霍普金斯狼疮队列

• 批准号: 8460769
• 负责人: MICHELLE A PETRI
• 金额: $ 60.9万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-09-30 至 2014-08-25
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8460769
• 关键词: Accounting; Acute; Address; African American; Antiphospholipid Antibodies; Arteries; Aspirin; Atherosclerosis; Autoantibodies; Basic Science; Biological Assay; Biological Markers; Biopsy; Blood Clot; Blood Platelets; Blood coagulation; Cardiac; Cause of Death; Clinical; Coagulation Process; Collaborations; Complement; Complement Activation; Coronary; Coronary Arteriosclerosis; Data; Development; Event; Future; General Population; Gold; Health; Hemostatic function; High Density Lipoproteins; Homocysteine; Homocystine; Human; Hydroxychloroquine; Hyperlipidemia; Hypertension; Individual; Inflammation; Inflammation Mediators; Inflammatory; Kidney; Kidney Diseases; Kidney Failure; Kidney Transplantation; Laboratories; Lead; Lupus; Lupus Coagulation Inhibitor; Lupus Nephritis; Measures; Modeling; Mus; Obesity; Organ; Outcome; Pathway interactions; Patients; Phenotype; Prevention strategy; Principal Investigator; Risk; Risk Factors; Spiral Computed Tomography; Statistical Methods; Stem cells; Systemic Lupus Erythematosus; Testing; Thrombophilia; Thrombosis; Transplant Recipients; Urine; Validation; Venous Thrombosis; Warfarin; Work; cardiovascular risk factor; chemokine; clinical care; cohort; cytokine; experience; follow-up; improved; mortality; novel strategies; programs; prophylactic; protein profiling; radiologist; response; rheumatologist; urinary

DESCRIPTION (provided by applicant): Traditional cardiovascular risk factors do not entirely account for the increased risk of atherosclerosis, the major cause of death, in systemic lupus erythematosus (SLE). In this project we want to identify new pathogenic pathways of atherosclerosis in SLE patients, by assessing the association between newly identified potential risk factors and a refined measure of subclinical atherosclerosis, soft (noncalcified) coronary plaque. Similarly over 50% of SLE patients develop lupus nephritis, including 75% of African-American SLE patients. Renal biopsy is the gold standard to determine renal activity, but is expensive, invasive, and has real risk to the patient. We hypothesize that urinary markers of renal activity will have clinical utility in human lupus nephritis, as they have in renal transplant patients and murine models of SLE. In addition we want to develop and study three new approaches to assess hypercoagulability risk (endogenous thrombogenic potential, complement activation, and platelet microparticles) to determine if these markers can predict future thrombotic events or associated with antiphospholipid antibodies.

描述（由申请人提供）：传统的心血管危险因素并不能完全解释全身性狼疮性红血病（SLE）中动脉粥样硬化的风险增加，这是主要的死亡原因。在这个项目中，我们希望通过评估新鉴定的潜在危险因素与亚临床动脉粥样硬化，软（非定量）冠状动脉斑块之间的关联来确定SLE患者动脉粥样硬化的新致病途径。同样，超过50％的SLE患者患有狼疮肾炎，包括75％的非裔美国人SLE患者。肾脏活检是确定肾脏活动的黄金标准，但昂贵，侵入性并且对患者具有真正的风险。我们假设肾脏活性的尿标志物将在人类狼疮肾炎中具有临床效用，就像它们在肾脏移植患者和SLE的鼠模型中一样。此外，我们还希望开发和研究三种新方法来评估高凝风险风险（内源性血栓形成潜力，补体激活和血小板微粒），以确定这些标记是否可以预测未来的血栓形成事件或与抗磷脂抗体有关。